Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

To demonstrate that Micardis and Altace when used together are more effective at lowering blood pres sure...

Date First Received: January 24, 2006

Last Updated: December 18, 2007

Verified by: Boehringer Ingelheim Pharmaceuticals, December 2007

Clinical Trial Phase: Phase 3 | Start Date: 

Overall Status: Completed

Estimated Enrollment: 1300

Brief Summary

Official Title: “A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3x4 Factorial Design Trial to Evaluate Telmisartan 20 and 80 mg Tablets in Combination With Ramipril 1.25, 10, and 20 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-Study”

Condition Keyword(s):

To demonstrate that Micardis and Altace when used together are more effective at lowering blood pres sure.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment

Intervention(s) in this Clinical Trial

  • Drug: Telmisartan
  • Drug: Ramipril

Outcome Measures for this Clinical Trial

Primary Measures

  • Change from baseline in seated trough Diastolic Blood pressure after 8 weeks of treatment

Secondary Measures

  • Change from baseline in systolic blood pressure after 8 weeks of treatment Percentage of patients responding to treatment Changes from baseline in diastolic and systolic blood pressure hourly means over the 24 hour dosing interval as measured by ABPM

Criteria for Participation in this Clinical Trial

Main Inclusion Criteria:

  • Male and female patients >=18 years of age with Stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure >=95 and <=119 mmHg

Main Exclusion Criteria:

  • Pregnant
  • Breast-feeding
  • Unwilling to use birth control during the study
  • Secondary hypertension, SBP>=180 mmHg, DBP>=120 mmHg
  • Severe renal dysfunction
  • Hepatic insufficiency
  • Stroke within the last 6 months
  • Myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months
  • Unstable or uncontrolled diabetes
  • History of angioedema of either of the study drugs, and hypersensitivity to the study drugs

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: Boehringer Ingelheim Pharmaceuticals

Overall Clinical Trial Officials and Contacts

Boehringer Ingelheim Study Coordinator Study Chair Boehringer Ingelheim Pharmaceuticals  

Additional Information

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00281593

Study ID Number: 1236.1

ClinicalTrials.gov Identifier: NCT00281593

Health Authority: United States: Food and Drug Administration

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.